Cory Sago
Chief Executive Officer Amplitude Therapeutics
Seminars
Tuesday 21st July 2026
CEO & mRNA Leaders Think Tank: From CAR-T Platforms, Gene Editing Triumphs & Cancer Immunotherapy Clinical Advances; Navigating mRNA’s Potential into New Therapies & Tools Towards Better Drugs for Patients Faster
9:00 am
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
Tuesday 21st July 2026
Development of Trans-Amplifying RNAs to Enable Robust Expression Across Multiple Species
3:45 pm
- Trans-amplifying RNA (taRNA) combines the advantages of modified mRNA and self-amplifying RNAs
- taRNA leads to increased peak expression as compared to modified mRNA at a fraction of the total RNA dose
- Multiple datasets demonstrating the potency, tolerability, and species translatability of taRNA
